J Cosmet Dermatol. 2016 Sep 16. doi: 10.1111/jocd.12285.

[Epub ahead of print]

The effects of a multigrowth factor-containing

cream on recovery after laser treatment: a
double-blinded, randomized, split-face
controlled study.
Shin S1, Shin JU1, Lee Y1, Kwon TG1, Lee JH2.

Author information
Abstract
BACKGROUND:
Patients who receive laser treatments may experience transient erythema, edema, and crusts
for several days. Although a variety of growth factor-containing creams for promoting
recovery after laser treatment are available, evidence for their efficacy remains insufficient.
AIMS:
We performed a randomized controlled split-face study to assess the effects of a multigrowth
factor (MGF)-containing cream on patients recovering from laser treatment.
MATERIALS AND METHODS:
Twenty patients underwent treatment using an ablative fractional laser and were randomized
with respect to the side of the face treated with an MGF-containing cream or control cream.
We measured post-treatment erythema and pigmentation using the erythema and melanin
indices, respectively, and evaluated the total area of microcrusts with dermoscopy.
Additionally, patient satisfaction levels and global improvement scores were assessed.
RESULTS:
We found that the area of microcrusts was significantly smaller in the MGF-treated regions.
Global improvement scores for post-treatment edema and wrinkles were also significantly
higher for MGF cream-treated sides than for the control sides.
CONCLUSION:
The MGF cream-treated regions showed a more rapid recovery from crusts and edema. Thus,
the use of an MGF-containing cream after laser treatment can effectively reduce recovery
time.
2016 Wiley Periodicals, Inc.

J Periodontol. 2016 Oct 7:1-10. [Epub ahead of print]

1.2% Rosuvastatin and 1.2% Atorvastatin Gel

Local Drug Delivery and Redelivery in the
Treatment of Class II Furcation Defects: A
Randomized Controlled Clinical Trial.
Garg S1, Pradeep AR1.

Author information
Abstract
BACKGROUND:
Statins are one of the lipid lowering drugs that help in reducing cholesterol levels in the body
by specifically inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase; which is a rate
limiting enzyme for cholesterol synthesis. Rosuvastatin (RSV) and atorvastatin (ATV) have
shown to have bone stimulatory and anti-inflammatory effects. The present study aims to
explore the efficacy of 1.2% RSV and 1.2% ATV gel as a local drug delivery and redelivery
system as an adjunct to scaling and root planing (SRP) for the treatment of class II furcation
defects.
METHODS:
Ninety patients with mandibular buccal class II furcation defects were randomly allocated
into three treatment groups: SRP with placebo gel (group 1), SRP with 1.2% RSV gel (group
2) and SRP with 1.2% ATV gel (group3). Clinical and radiographic parameters were recorded
at baseline then after 6 months. The gels were redelivered at the respective sites at this 6
month appointment. Then again all clinical and radiographic parameters were recorded after 3
months. (9 months from baseline).
RESULTS:
Greater mean probing depth (PD) reduction and greater mean gain in relative vertical clinical
attachment level (RVCAL) and relative horizontal clinical attachment level (RHCAL) were
seen in the RSV group than ATV group at 6 and 9 months. Furthermore, a significantly
greater mean percentage of defect depth reduction was found in the RSV group (30.808.35,
41.866.76) than ATV group (25.548.89, 34.318.04) at 6 and 9 months, respectively.
CONCLUSION:
RSV group showed significant improvement in all clinical parameters along with
significantly greater defect depth reduction as compared to ATV group in treatment of
mandibular class II furcation defects as an adjunct to SRP.